Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 5/20 | 0.52 |
| ▸ | LGALS4 | P56470 | 4/20 | 0.52 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.49 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521368 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL12807943 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL1682156 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL9545439 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL12595600 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL24192986 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL14413230 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL19869143 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL7150482 | 0.93 | LGALS8 (0.53) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL8658236 | 0.93 | LGALS3 (0.46) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267940-A1 | Method for Producing 4-Deoxy-4-Fluoro-D-Glucose Derivative | CENTRAL GLASS COMPANY, LIMITED (JP) | 2010-10-21 | — | — | US | claimed |
| EP-2216337-A1 | METHOD FOR PRODUCING 4-DEOXY-4-FLUORO-D-GLUCOSE DERIVATIVE | Central Glass Company, Limited (JP) | 2010-08-11 | — | — | EP | claimed |
| CN-113015432-B | Compositions comprising sulfated galactose and embodiments thereof | SEA6能源私人有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-10174132-B2 | Heparan sulfate synthesis | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20160060365-A1 | HEPARAN SULFATE SYNTHESIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2016-03-03 | — | — | US | disclosed |
| EP-2406270-B1 | METHOD FOR MANUFACTURING 4-FLUORO-4-DESOXY-ALPHA-D-GLUCOPYRANOSIDES | SANOFI SA (FR) | 2013-04-17 | — | — | EP | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2482823-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI (FR) | 2012-08-08 | — | — | EP | disclosed |
| US-20120142560-A1 | HEPARAN SULFATE SYNTHESIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| US-20100267940-A1 | Method for Producing 4-Deoxy-4-Fluoro-D-Glucose Derivative | CENTRAL GLASS COMPANY, LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| WO-2004052902-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052903-A1 | NOVEL FLUOROGLYCOSIDE HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | WO | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267940-A1 | Method for Producing 4-Deoxy-4-Fluoro-D-Glucose Derivative | SLC5A2, PFKFB3, PFKFB2 | LGALS3 160/4885LGALS4 120/4885LGALS9 86/4885 |
| US-10174132-B2 | Heparan sulfate synthesis | HPSE, STT3B, DDOST | LGALS3 250/4885LGALS4 169/4885LGALS9 258/4885 |
| US-20160060365-A1 | HEPARAN SULFATE SYNTHESIS | HPSE, STT3B, DDOST | LGALS3 250/4885LGALS4 169/4885LGALS9 258/4885 |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SLC5A1, SLC5A2, SOST | LGALS3 240/4885LGALS4 199/4885LGALS9 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.